4//SEC Filing
AVADEL PHARMACEUTICALS PLC 4
Accession 0001140361-17-021796
$AVDLCIK 0001012477operating
Filed
May 21, 8:00 PM ET
Accepted
May 22, 6:20 PM ET
Size
13.0 KB
Accession
0001140361-17-021796
Insider Transaction Report
Form 4
ANDERSON MICHAEL S
DirectorChief Executive Officer
Transactions
- Purchase
ADSs
2017-05-19$10.00/sh+2,500$25,000→ 225,750 total
Holdings
- 200,000
Stock Option (right to buy)
Exercise: $16.30Exp: 2024-12-11→ ADSs (200,000 underlying) - 200,000
Stock Option (right to buy)
Exercise: $14.35Exp: 2025-12-10→ ADSs (200,000 underlying) - 200,000
Stock Option (right to buy)
Exercise: $10.40Exp: 2026-12-14→ ADSs (200,000 underlying) - 275,000
Stock Option (right to buy)
Exercise: $6.93Exp: 2022-03-08→ ADSs (275,000 underlying) - 80,500
Stock Option (right to buy)
Exercise: $4.07Exp: 2023-02-01→ ADSs (80,500 underlying)
Footnotes (8)
- [F1]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- [F2]Includes (a) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (c) 30,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.01, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3).
- [F4]Options became exercisable in four equal amounts over the first four anniversaries after the 03/08/2012 grant date.
- [F5]Options become exercisable as to 20,125 ADSs on each of the first four anniversaries after the 02/01/2013 grant date.
- [F6]Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
- [F7]Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- [F8]Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Documents
Issuer
AVADEL PHARMACEUTICALS PLC
CIK 0001012477
Entity typeoperating
Related Parties
1- filerCIK 0001012477
Filing Metadata
- Form type
- 4
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 6:20 PM ET
- Size
- 13.0 KB